

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1498)**

## **APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of PuraPharm Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Norimoto Hisayoshi (範本文哲) (“**Dr. Norimoto**”) has been appointed as an executive Director of the Company with effect from 17 November 2020.

The biographical details of Dr. Norimoto are as follows:

Dr. Norimoto, aged 50, is the chief research and development (“**R&D**”) officer of the Group, the general manager of PuraPharm Japan Corporation and SODX Co., Ltd. in Osaka in Japan and the vice president of production and operation in China of the Group. Dr. Norimoto is primarily responsible for the management of the R&D, operation and production of the Group in China and Japan. Dr. Norimoto joined the Group in March 2016 as the general manager of PuraPharm Japan Corporation.

Prior to joining the Group, from 2001 to 2016, Dr. Norimoto was the pharmacological head of R&D at Kracie Pharmaceutical, Ltd, a historical Kampo pharmaceutical manufacturer in Japan. Dr. Norimoto has been a director of Association for Promoting Sustainable Use of Medicinal Resources of Japan since 2018, a senior expert in the Committee of Planting and Breeding of China Association of Traditional Chinese Medicine in China since December 2019 and the chapter coordinator of Japan region for the Consortium for Globalisation of Chinese Medicine since 2018.

Dr. Norimoto received a Master’s Degree in pharmaceutical science and the Doctor of Philosophy in pharmaceutical science from the National Toyama Medical and Pharmaceutical University (now known as the University of Toyama) in Japan in 1998 and 2001, respectively.

Dr. Norimoto will enter into a service contract with the Company for his appointment as the executive Director for a term of 3 years commencing from 17 November 2020. Dr. Norimoto is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association (the “**Articles**”) of the Company and the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). According to the Articles, Dr. Norimoto will be subject to re-election at the next annual general meeting of the Company. Under the said service contract, Dr. Norimoto will be entitled to a directors’ fee of Japanese Yen 2,025,000 (equivalent to approximately HK\$151,875\*) per month, further options to be granted by the Board under the share option scheme of the Company and discretionary bonus, which will be determined by the Board from time to time with reference to his performance and the performance of the Group. The remuneration package of Dr. Norimoto was recommended by the remuneration committee of the Company with reference to his qualifications, duties, responsibilities and expertise expected to be devoted to the Company’s affairs and the prevailing market conditions.

As at the date of this announcement, Dr. Norimoto is beneficially interested in 370,000 shares which may fall to be issued upon exercise of the 370,000 options granted to him under the share option scheme of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, Dr. Norimoto (i) does not hold any other position in the Company or other members of the Group as at the date of this announcement; (ii) does not hold any directorships in any public companies, the securities of which are listed on the Stock Exchange or on any securities market overseas in the last three years preceding the date of this announcement; and (iii) does not have any relationships with other Directors, members of the senior management, substantial shareholders or controlling shareholders of the Company as at the date of this announcement within the meaning of the Listing Rules.

Save as disclosed above, there are no other information relating to the appointment of Dr. Norimoto which shall be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Company would like to welcome Dr. Norimoto in joining the Board.

By order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman*

Hong Kong, 10 November 2020

*As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Cheong Shin Keong, and Ms. Man Yee Wai, Viola; non-executive directors of the Company are Mr. Chow, Stanley and Mr. Chan Kin Man, Eddie; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.*

\* *For the purpose of this announcement, the exchange rate of Japanese Yen 100=HK\$7.5 has been used for illustrative purpose only.*